1. Home
  2. NUS vs CGEM Comparison

NUS vs CGEM Comparison

Compare NUS & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nu Skin Enterprises Inc.

NUS

Nu Skin Enterprises Inc.

HOLD

Current Price

$10.19

Market Cap

603.4M

Sector

Health Care

ML Signal

HOLD

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$12.28

Market Cap

671.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUS
CGEM
Founded
1984
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Other Pharmaceuticals
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
603.4M
671.7M
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
NUS
CGEM
Price
$10.19
$12.28
Analyst Decision
Hold
Strong Buy
Analyst Count
1
8
Target Price
$7.00
$28.00
AVG Volume (30 Days)
430.0K
1.3M
Earning Date
11-06-2025
11-06-2025
Dividend Yield
2.40%
N/A
EPS Growth
N/A
N/A
EPS
2.20
N/A
Revenue
$1,560,391,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2.12
N/A
P/E Ratio
$4.53
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.32
$5.68
52 Week High
$14.62
$13.60

Technical Indicators

Market Signals
Indicator
NUS
CGEM
Relative Strength Index (RSI) 52.15 65.27
Support Level $9.63 $10.01
Resistance Level $10.18 $12.88
Average True Range (ATR) 0.33 1.22
MACD 0.07 0.12
Stochastic Oscillator 76.32 75.44

Price Performance

Historical Comparison
NUS
CGEM

About NUS Nu Skin Enterprises Inc.

Nu Skin Enterprises Inc is a health and beauty direct-selling company. It has two primary product categories: beauty products and wellness products. The company develops and distributes nutritional, weight-management products, and food supplements under the Nu Skin and Pharmanex brands, respectively. The company has operations internationally, in more than 50 countries across the Americas, Europe, and the Asia-Pacific.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.

Share on Social Networks: